These findings renewed the interest in therapeutic agents that target inflammatory pathways in cardiovascular disease, including colchicine (LoDoCo2, ACRTN12614000093684, CLEAR-SYNERGY, NCT03048825 and CONVINCE, NCT02898610), IL-2 (LILACS, NCT03113773), and agents that act on the IL-1β/IL-6 signaling pathway. Here, IL1B is linked to cardiovascular disorder.